Hologic, Inc. (NASDAQ:HOLX) Short Interest Up 6.4% in January

Hologic, Inc. (NASDAQ:HOLX) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,510,000 shares, an increase of 6.4% from the December 31st total of 5,180,000 shares. Currently, 2.5% of the company’s stock are short sold. Based on an average daily volume of 1,910,000 shares, the days-to-cover ratio is presently 2.9 days.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hologic

Hedge funds have recently bought and sold shares of the stock. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the 3rd quarter worth about $25,000. General Partner Inc. bought a new stake in Hologic in the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Finally, Sunbelt Securities Inc. purchased a new position in shares of Hologic during the second quarter worth approximately $37,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.6 %

Shares of HOLX stock opened at $71.72 on Tuesday. Hologic has a 52-week low of $68.61 and a 52-week high of $84.67. The business’s fifty day moving average is $73.19 and its 200 day moving average is $78.03. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a market capitalization of $16.19 billion, a PE ratio of 21.54, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 EPS. On average, equities research analysts anticipate that Hologic will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on HOLX. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, Royal Bank of Canada lifted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.